AGT T174M

The Angiotensinogen Variant — Blood Pressure Genetics in the Renin-Angiotensin System

Angiotensinogen (AGT) is the essential precursor protein of the renin-angiotensin system (RAS), the body's
primary long-term regulator of blood pressure and fluid balance. The kidney enzyme renin cleaves AGT to
produce angiotensin I, which is then converted by ACE to angiotensin II | the vasoactive peptide that
raises blood pressure by constricting blood vessels and signaling the adrenal glands to release
aldosterone. The T174M variant (rs4762) is one of two
well-studied missense changes in AGT — alongside [M235T (rs699) | the more frequently studied AGT
variant, which is in strong linkage disequilibrium with T174M in many populations] — and both have been
investigated for decades as candidates for genetically elevated blood pressure.

The Mechanism

AGT sits on the minus strand of chromosome 1 at position 230,710,231 (GRCh38). The rs4762 G>A change
on the plus strand produces a Threonine-to-Methionine substitution at position 198 of the angiotensinogen
precursor | also described as T174M in older literature counting from the mature protein after signal
peptide cleavage. This amino acid change in the AGT protein is
thought to affect its rate of cleavage by renin and its plasma concentration | carriers of the A allele
tend to have higher circulating angiotensinogen levels,
shifting the equilibrium of the entire RAS toward higher angiotensin II output. Higher angiotensin II
drives sustained increases in vascular tone, sodium retention, and — over years — contributes to
hypertension and end-organ damage.

The Evidence

The AGT gene's role in hypertension was first established in 1992 | Jeunemaitre et al., "Molecular
basis of human hypertension: role of angiotensinogen." Cell 71:169-80,
when genetic linkage between AGT variants and hypertension was demonstrated in two large independent
family panels. This landmark paper showed that AGT molecular variants were inherited predispositions to
essential hypertension and that plasma AGT concentrations differed by genotype.

The cardiovascular consequences of rs4762 were quantified in a
2021 meta-analysis of 7,657 subjects across 11 studies | Li et al., "Myocardial Infarction and AGT
p.Thr174Met Polymorphism: A Meta-Analysis of 7657 Subjects." Cardiovascular Therapeutics
2021. The A (Met174) allele significantly increased
myocardial infarction risk: OR 2.26 (95% CI 1.35–3.77) under the recessive model, OR 1.13 (95% CI
1.02–1.26) under the dominant model, and OR 1.36 (95% CI 1.13–1.64) under the additive model. Effects
were strongest in Asian populations; Caucasian subgroup analyses did not reach statistical significance.

Park et al. 2013 | "Assessment of two missense polymorphisms (rs4762 and rs699) of the angiotensinogen
gene and stroke." Experimental and Therapeutic Medicine 5:343-349
examined 197 stroke patients and 301 controls, finding that the rs4762 A (T allele on coding strand)
allele was associated with [intracerebral hemorrhage | 16.2% allele frequency in ICH vs 9.6% in
controls, P=0.021] and correlated with worse neurological severity scores. Ischemic stroke was not
significantly associated.

In a Mexican cohort of 546 adults with diabetic nephropathy,
Vázquez-Moreno et al. 2021 | "AGT rs4762 is associated with diastolic blood pressure in Mexicans
with diabetic nephropathy." Journal of Diabetes and Its Complications 35(3)
found that the A allele predicted higher diastolic blood pressure specifically in those with established
kidney disease (β=2.84, P=0.026), an important finding because diastolic hypertension drives
progression of diabetic nephropathy.

A 2018 study in Han Chinese women | Zhou et al., Biomed Res Int 2018, n=156 preeclampsia / 286
controls identified rs4762 as one of seven alleles
significantly associated with preeclampsia susceptibility. Notably, a large
2016 meta-analysis of 95 case-control studies | Zhang et al., Medical Science Monitor,
n=16,646 PE patients / 28,901 controls found no overall
significant association of rs4762 with preeclampsia across all ancestries combined, suggesting
population-specific effects — consistent with the pattern seen for MI risk.

Practical Implications

The A allele raises circulating angiotensinogen and tips the RAS toward sustained vasoconstriction.
For carriers, this is not destiny — the RAS is highly modifiable by both lifestyle and medication.
RAS-targeting medications (ACE inhibitors, ARBs) act downstream of AGT and are among the most effective
antihypertensives available. Dietary sodium directly amplifies RAS activation: each gram of excess
sodium per day substantially raises angiotensin II-driven pressure in those with genetically elevated
AGT. Conversely, [low-sodium dietary patterns | below 2,300 mg/day, or ideally 1,500 mg/day for
those at elevated cardiovascular risk] are among the most potent non-pharmacological strategies for
blunting AGT-mediated pressure elevation.

Interactions

rs4762 is in linkage disequilibrium with rs699 (M235T) | the two variants are often co-inherited and
studied as a haplotype block. Haplotype analyses
consistently show stronger associations with blood pressure and cardiovascular disease than either
SNP alone. The AGT gene also interacts with [rs5186 (AGTR1 A1166C) | the angiotensin II type 1
receptor variant] — when both the AGT signal peptide and the AT1 receptor are variant, the
downstream pressor response is amplified. In women, AGT haplotypes interact significantly with
hypertension status to modulate coronary artery disease risk, a gene-environment interaction that
may partly explain sex-specific cardiovascular risk patterns.